The genetics of celiac disease: A comprehensive review of clinical implications

Journal of Autoimmunity

Volumn 64, Issue , 2015, Pages 26-41

  Dieli Crimi, Romina ^a   Cénit, M Carmen ^b,c   Núñez, Concepción ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^c INSTITUTO DE AGROQUÍMICA Y TECNOLOGÍA DE ALIMENTOS CSIC   (Spain)

Author keywords

Celiac disease; Epigenetics; Gene expression; HLA; Microbiota

Indexed keywords

CD4 ANTIGEN;

B LYMPHOCYTE; CELIAC DISEASE; EPIGENETICS; GENE EXPRESSION; GENE LOCUS; GENETIC RISK; GENETIC VARIABILITY; GLUTEN FREE DIET; HLA SYSTEM; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; MICROFLORA; MOLECULAR EPIDEMIOLOGY; MOLECULAR GENETICS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; ANIMAL; GENETIC ASSOCIATION STUDY; GENETIC EPIGENESIS; GENETIC PREDISPOSITION; GENETIC VARIATION; GENETICS; IMMUNOLOGY; INTESTINE FLORA; MICROBIOLOGY; RISK;

ANIMALS; CELIAC DISEASE; EPIGENESIS, GENETIC; GASTROINTESTINAL MICROBIOME; GENETIC ASSOCIATION STUDIES; GENETIC LOCI; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; RISK;

EID: 84946483911     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2015.07.003     Document Type: Review

References (185)

1. Husby S., Koletzko S., Korponay-Szabo I.R., Mearin M.L., Phillips A., Shamir R., et al. European Society for pediatric gastroenterology, hepatology, and nutrition guidelines for the diagnosis of coeliac disease. J. Pediatr. Gastroenterol. Nutr. 2012, 54:136-160.
2. Dicke W.K., Weijers H.A., Van De Kamer J.H. Coeliac disease. II. The presence in wheat of a factor having a deleterious effect in cases of coeliac disease. Acta Paediatr. 1953, 42:34-42.
3. Catassi C., Ratsch I.M., Fabiani E., Rossini M., Bordicchia F., Candela F., et al. Coeliac disease in the year 2000: exploring the iceberg. Lancet 1994, 343:200-203.
4. Altobelli E., Paduano R., Petrocelli R., Di Orio F. Burden of celiac disease in Europe: a review of its childhood and adulthood prevalence and incidence as of September 2014. Ann. Ig. Med. Prevent. Comunita 2014, 26:485-498.
5. Myleus A., Ivarsson A., Webb C., Danielsson L., Hernell O., Hogberg L., et al. Celiac disease revealed in 3% of Swedish 12-year-olds born during an epidemic. J. Pediatr. Gastroenterol. Nutr. 2009, 49:170-176.
6. Ivarsson A., Persson L.A., Nystrom L., Ascher H., Cavell B., Danielsson L., et al. Epidemic of coeliac disease in Swedish children. Acta Paediatr. 2000, 89:165-171.
7. Olsson C., Hernell O., Hornell A., Lonnberg G., Ivarsson A. Difference in celiac disease risk between Swedish birth cohorts suggests an opportunity for primary prevention. Pediatrics 2008, 122:528-534.
8. Aronsson C.A., Lee H.S., Liu E., Uusitalo U., Hummel S., Yang J., et al. Age at gluten introduction and risk of celiac disease. Pediatrics 2015, 135:239-245.
9. Lionetti E., Castellaneta S., Francavilla R., Pulvirenti A., Tonutti E., Amarri S., et al. Introduction of gluten, HLA status, and the risk of celiac disease in children. N. Engl. J. Med. 2014, 371:1295-1303.
10. Vriezinga S.L., Auricchio R., Bravi E., Castillejo G., Chmielewska A., Crespo Escobar P., et al. Randomized feeding intervention in infants at high risk for celiac disease. N. Engl. J. Med. 2014, 371:1304-1315.
11. Whitacre C.C. Sex differences in autoimmune disease. Nat. Immunol. 2001, 2:777-780.
12. Ivarsson A., Persson L.A., Nystrom L., Hernell O. The Swedish coeliac disease epidemic with a prevailing twofold higher risk in girls compared to boys may reflect gender specific risk factors. Eur. J. Epidemiol. 2003, 18:677-684.
13. Mustalahti K., Catassi C., Reunanen A., Fabiani E., Heier M., McMillan S., et al. The prevalence of celiac disease in Europe: results of a centralized, international mass screening project. Ann. Med. 2010, 42:587-595.
14. Logan R.F.A. Problems and pitfalls in epidemiological studies of coeliac disease. Common Food Intolerances 1: Epidemiology of Coeliac Disease 1992, Karger, Basel, New York. S. Auricchio, J.K. Visakorpi (Eds.).
15. Biagi F., Klersy C., Balduzzi D., Corazza G.R. Are we not over-estimating the prevalence of coeliac disease in the general population?. Ann. Med. 2010, 42:557-561.
16. Greco L., Romino R., Coto I., Di Cosmo N., Percopo S., Maglio M., et al. The first large population based twin study of coeliac disease. Gut 2002, 50:624-628.
17. Nistico L., Fagnani C., Coto I., Percopo S., Cotichini R., Limongelli M.G., et al. Concordance, disease progression, and heritability of coeliac disease in Italian twins. Gut 2006, 55:803-808.
18. Risch N. Assessing the role of HLA-linked and unlinked determinants of disease. Am. J. Hum. Genet. 1987, 40:1-14.
19. Petronzelli F., Bonamico M., Ferrante P., Grillo R., Mora B., Mariani P., et al. Genetic contribution of the HLA region to the familial clustering of coeliac disease. Ann. Hum. Genet. 1997, 61:307-317.
20. Bevan S., Popat S., Braegger C.P., Busch A., O'Donoghue D., Falth-Magnusson K., et al. Contribution of the MHC region to the familial risk of coeliac disease. J. Med. Genet. 1999, 36:687-690.
21. Falchuk Z.M., Rogentine G.N., Strober W. Predominance of histocompatibility antigen HL-A8 in patients with gluten-sensitive enteropathy. J. Clin. Invest. 1972, 51:1602-1605.
22. Stokes P.L., Asquith P., Holmes G.K., Mackintosh P., Cooke W.T. Histocompatibility antigens associated with adult coeliac disease. Lancet 1972, 2:162-164.
23. Tosi R., Vismara D., Tanigaki N., Ferrara G.B., Cicimarra F., Buffolano W., et al. Evidence that celiac disease is primarily associated with a DC locus allelic specificity. Clin. Immunol. Immunopathol. 1983, 28:395-404.
24. Sollid L.M., Markussen G., Ek J., Gjerde H., Vartdal F., Thorsby E. Evidence for a primary association of celiac disease to a particular HLA-DQ alpha/beta heterodimer. J. Exp. Med. 1989, 169:345-350.
25. Keuning J.J., Pena A.S., van Leeuwen A., van Hooff J.P., va Rood J.J. HLA-DW3 associated with coeliac disease. Lancet 1976, 1:506-508.
26. Mearin M.L., Biemond I., Pena A.S., Polanco I., Vazquez C., Schreuder G.T., et al. HLA-DR phenotypes in Spanish coeliac children: their contribution to the understanding of the genetics of the disease. Gut 1983, 24:532-537.
27. Ploski R., Ek J., Thorsby E., Sollid L.M. On the HLA-DQ (alpha 1*0501, beta 1*0201)-associated susceptibility in celiac disease: a possible gene dosage effect of DQB1*0201. Tissue Antigens 1993, 41:173-177.
28. Louka A.S., Nilsson S., Olsson M., Talseth B., Lie B.A., Ek J., et al. HLA in coeliac disease families: a novel test of risk modification by the 'other' haplotype when at least one DQA1*05-DQB1*02 haplotype is carried. Tissue Antigens 2002, 60:147-154.
29. Spurkland A., Sollid L.M., Polanco I., Vartdal F., Thorsby E. HLA-DR and -DQ genotypes of celiac disease patients serologically typed to be non-DR3 or non-DR5/7. Hum. Immunol. 1992, 35:188-192.
30. Karell K., Louka A.S., Moodie S.J., Ascher H., Clot F., Greco L., et al. HLA types in celiac disease patients not carrying the DQA1*05-DQB1*02 (DQ2) heterodimer: results from the European genetics cluster on celiac disease. Hum. Immunol. 2003, 64:469-477.
31. Gutierrez-Achury J., Zhernakova A., Pulit S.L., Trynka G., Hunt K.A., Romanos J., et al. Fine mapping in the MHC region accounts for 18% additional genetic risk for celiac disease. Nat. Genet. 2015, 47:577-578.
32. Medrano L.M., Dema B., Lopez-Larios A., Maluenda C., Bodas A., Lopez-Palacios N., et al. HLA and celiac disease susceptibility: new genetic factors bring open questions about the HLA influence and gene-dosage effects. PloS One 2012, 7:e48403.
33. Bugawan T.L., Angelini G., Larrick J., Auricchio S., Ferrara G.B., Erlich H.A. A combination of a particular HLA-DP beta allele and an HLA-DQ heterodimer confers susceptibility to coeliac disease. Nature 1989, 339:470-473.
34. Kagnoff M.F., Harwood J.I., Bugawan T.L., Erlich H.A. Structural analysis of the HLA-DR, -DQ, and -DP alleles on the celiac disease-associated HLA-DR3 (DRw17) haplotype. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:6274-6278.
35. Hadley D., Hagopian W., Liu E., She J.X., Simell O., Akolkar B., et al. HLA-DPB1*04:01 protects genetically susceptible children from celiac disease autoimmunity in the TEDDY Study. Am. J. Gastroenterol. 2015, 110:915-920.
36. van Heel D.A., Franke L., Hunt K.A., Gwilliam R., Zhernakova A., Inouye M., et al. A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21. Nat. Genet. 2007, 39:827-829.
37. Zhernakova A., Alizadeh B.Z., Bevova M., van Leeuwen M.A., Coenen M.J., Franke B., et al. Novel association in chromosome 4q27 region with rheumatoid arthritis and confirmation of type 1 diabetes point to a general risk locus for autoimmune diseases. Am. J. Hum. Genet. 2007, 81:1284-1288.
38. Festen E.A., Goyette P., Scott R., Annese V., Zhernakova A., Lian J., et al. Genetic variants in the region harbouring IL2/IL21 associated with ulcerative colitis. Gut 2009, 58:799-804.
39. Hughes T., Kim-Howard X., Kelly J.A., Kaufman K.M., Langefeld C.D., Ziegler J., et al. Fine-mapping and transethnic genotyping establish IL2/IL21 genetic association with lupus and localize this genetic effect to IL21. Arthr. Rheumat. 2011, 63:1689-1697.
40. Hunt K.A., Zhernakova A., Turner G., Heap G.A., Franke L., Bruinenberg M., et al. Newly identified genetic risk variants for celiac disease related to the immune response. Nat. Genet. 2008, 40:395-402.
41. Garner C.P., Murray J.A., Ding Y.C., Tien Z., van Heel D.A., Neuhausen S.L. Replication of celiac disease UK genome-wide association study results in a US population. Hum. Mol. Genet. 2009, 18:4219-4225.
42. Trynka G., Zhernakova A., Romanos J., Franke L., Hunt K.A., Turner G., et al. Coeliac disease-associated risk variants in TNFAIP3 and REL implicate altered NF-kappaB signalling. Gut 2009, 58:1078-1083.
43. Dubois P.C., Trynka G., Franke L., Hunt K.A., Romanos J., Curtotti A., et al. Multiple common variants for celiac disease influencing immune gene expression. Nat. Genet. 2010, 42:295-302.
44. Cotsapas C., Voight B.F., Rossin E., Lage K., Neale B.M., Wallace C., et al. Pervasive sharing of genetic effects in autoimmune disease. PLoS Genet. 2011, 7:e1002254.
45. Kumar V., Wijmenga C., Xavier R.J. Genetics of immune-mediated disorders: from genome-wide association to molecular mechanism. Curr. Opin. Immunol. 2014, 31:51-57.
46. Smyth D.J., Plagnol V., Walker N.M., Cooper J.D., Downes K., Yang J.H., et al. Shared and distinct genetic variants in type 1 diabetes and celiac disease. N. Engl. J. Med. 2008, 359:2767-2777.
47. Festen E.A., Goyette P., Green T., Boucher G., Beauchamp C., Trynka G., et al. A meta-analysis of genome-wide association scans identifies IL18RAP, PTPN2, TAGAP, and PUS10 as shared risk loci for Crohn's disease and celiac disease. PLoS Genet. 2011, 7:e1001283.
48. Trynka G., Hunt K.A., Bockett N.A., Romanos J., Mistry V., Szperl A., et al. Dense genotyping identifies and localizes multiple common and rare variant association signals in celiac disease. Nat. Genet. 2011, 43:1193-1201.
49. Ostensson M., Monten C., Bacelis J., Gudjonsdottir A.H., Adamovic S., Ek J., et al. A possible mechanism behind autoimmune disorders discovered by genome-wide linkage and association analysis in celiac disease. PloS One 2013, 8:e70174.
50. Coleman C., Quinn E.M., Ryan A.W., Conroy J., Trimble V., Mahmud N., et al. Common polygenic variation in coeliac disease and confirmation of ZNF335 and NIFA as disease susceptibility loci. Eur. J. Hum. Genet. 2015 Apr 29, (Epub ahead of print). 10.1038/ejhg.2015.87.
51. Hunt K.A., Mistry V., Bockett N.A., Ahmad T., Ban M., Barker J.N., et al. Negligible impact of rare autoimmune-locus coding-region variants on missing heritability. Nature 2013, 498:232-235.
52. Mistry V., Bockett N.A., Levine A.P., Mirza M.M., Hunt K.A., Ciclitira P.J., et al. Exome sequencing of 75 individuals from multiply affected coeliac families and large scale resequencing follow up. PloS One 2015, 10:e0116845.
53. Kundaje A., Meuleman W., Ernst J., Bilenky M., Yen A., Heravi-Moussavi A., et al. Integrative analysis of 111 reference human epigenomes. Nature 2015, 518:317-330.
54. Ricano-Ponce I., Wijmenga C. Mapping of immune-mediated disease genes. Annu. Rev. Genom. Hum. Genet. 2013, 14:325-353.
55. Birney E., Stamatoyannopoulos J.A., Dutta A., Guigo R., Gingeras T.R., Margulies E.H., et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 2007, 447:799-816.
56. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
57. Shibayama Y., Fanucchi S., Magagula L., Mhlanga M.M. lncRNA and gene looping: what's the connection?. Transcription 2014, 5:e28658.
58. Morlando M., Ballarino M., Fatica A., Bozzoni I. The role of long noncoding RNAs in the epigenetic control of gene expression. ChemMedChem 2014, 9:505-510.
59. Cesana M., Cacchiarelli D., Legnini I., Santini T., Sthandier O., Chinappi M., et al. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell 2011, 147:358-369.
60. Stachurska A., Zorro M.M., van der Sijde M.R., Withoff S. Small and long regulatory RNAs in the immune system and immune diseases. Front. Immunol. 2014, 5:513.
61. McKenna L.B., Schug J., Vourekas A., McKenna J.B., Bramswig N.C., Friedman J.R., et al. MicroRNAs control intestinal epithelial differentiation, architecture, and barrier function. Gastroenterology 2010, 139. 1654-64, 64.e1.
62. Griffiths-Jones S., Saini H.K., van Dongen S., Enright A.J. miRBase: tools for microRNA genomics. Nucleic Acids Res. 2008, 36:D154-D158.
63. Capuano M., Iaffaldano L., Tinto N., Montanaro D., Capobianco V., Izzo V., et al. MicroRNA-449a overexpression, reduced NOTCH1 signals and scarce goblet cells characterize the small intestine of celiac patients. PloS One 2011, 6:e29094.
64. Iborra M., Bernuzzi F., Invernizzi P., Danese S. MicroRNAs in autoimmunity and inflammatory bowel disease: crucial regulators in immune response. Autoimmun. Rev. 2012, 11:305-314.
65. Vaira V., Roncoroni L., Barisani D., Gaudioso G., Bosari S., Bulfamante G., et al. MicroRNA profiles in coeliac patients distinguish different clinical phenotypes and are modulated by gliadin peptides in primary duodenal fibroblasts. Clin. Sci. Lond. Engl. 1979 2014, 126:417-423.
66. Magni S., Buoli Comani G., Elli L., Vanessi S., Ballarini E., Nicolini G., et al. miRNAs affect the expression of innate and adaptive immunity proteins in celiac disease. Am. J. Gastroenterol. 2014, 109:1662-1674.
67. Kumar V., Wijmenga C., Withoff S. From genome-wide association studies to disease mechanisms: celiac disease as a model for autoimmune diseases. Semin. Immunopathol. 2012, 34:567-580.
68. Cabili M.N., Trapnell C., Goff L., Koziol M., Tazon-Vega B., Regev A., et al. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev. 2011, 25:1915-1927.
69. Kumar V., Gutierrez-Achury J., Kanduri K., Almeida R., Hrdlickova B., Zhernakova D.V., et al. Systematic annotation of celiac disease loci refines pathological pathways and suggests a genetic explanation for increased interferon-gamma levels. Hum. Mol. Genet. 2015, 24:397-409.
70. Plaza-Izurieta L., Fernandez-Jimenez N., Irastorza I., Jauregi-Miguel A., Romero-Garmendia I., Vitoria J.C., et al. Expression analysis in intestinal mucosa reveals complex relations among genes under the association peaks in celiac disease. Eur. J. Hum. Genet. EJHG 2014 Nov 12, (Epub ahead of print). 10.1038/ejhg.2014.244.
71. Manichanh C., Rigottier-Gois L., Bonnaud E., Gloux K., Pelletier E., Frangeul L., et al. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut 2006, 55:205-211.
72. Machiels K., Joossens M., Sabino J., De Preter V., Arijs I., Eeckhaut V., et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 2014, 63:1275-1283.
73. Wen L., Ley R.E., Volchkov P.Y., Stranges P.B., Avanesyan L., Stonebraker A.C., et al. Innate immunity and intestinal microbiota in the development of type 1 diabetes. Nature 2008, 455:1109-1113.
74. Brusca S.B., Abramson S.B., Scher J.U. Microbiome and mucosal inflammation as extra-articular triggers for rheumatoid arthritis and autoimmunity. Curr. Opin. Rheumatol. 2014, 26:101-107.
75. Akobeng A.K., Ramanan A.V., Buchan I., Heller R.F. Effect of breast feeding on risk of coeliac disease: a systematic review and meta-analysis of observational studies. Arch. Dis. Child. 2006, 91:39-43.
76. Decker E., Engelmann G., Findeisen A., Gerner P., Laass M., Ney D., et al. Cesarean delivery is associated with celiac disease but not inflammatory bowel disease in children. Pediatrics 2010, 125:e1433-e1440.
77. Wacklin P., Kaukinen K., Tuovinen E., Collin P., Lindfors K., Partanen J., et al. The duodenal microbiota composition of adult celiac disease patients is associated with the clinical manifestation of the disease. Inflamm. Bowel Dis. 2013, 19:934-941.
78. Wacklin P., Laurikka P., Lindfors K., Collin P., Salmi T., Lahdeaho M.L., et al. Altered duodenal microbiota composition in celiac disease patients suffering from persistent symptoms on a long-term gluten-free diet. Am. J. Gastroenterol. 2014, 109:1933-1941.
79. Collado M.C., Donat E., Ribes-Koninckx C., Calabuig M., Sanz Y. Imbalances in faecal and duodenal Bifidobacterium species composition in active and non-active coeliac disease. BMC Microbiol. 2008, 8:232.
80. Collado M.C., Donat E., Ribes-Koninckx C., Calabuig M., Sanz Y. Specific duodenal and faecal bacterial groups associated with paediatric coeliac disease. J. Clin. Pathol. 2009, 62:264-269.
81. Nistal E., Caminero A., Vivas S., Ruiz de Morales J.M., Saenz de Miera L.E., Rodriguez-Aparicio L.B., et al. Differences in faecal bacteria populations and faecal bacteria metabolism in healthy adults and celiac disease patients. Biochimie 2012, 94:1724-1729.
82. Medina M., De Palma G., Ribes-Koninckx C., Calabuig M., Sanz Y. Bifidobacterium strains suppress in vitro the pro-inflammatory milieu triggered by the large intestinal microbiota of coeliac patients. J. Inflamm. Lond. Engl. 2008, 5:19.
83. Laparra J.M., Sanz Y. Bifidobacteria inhibit the inflammatory response induced by gliadins in intestinal epithelial cells via modifications of toxic peptide generation during digestion. J. Cell Biochem. 2010, 109:801-807.
84. Orlando A., Linsalata M., Notarnicola M., Tutino V., Russo F. Lactobacillus GG restoration of the gliadin induced epithelial barrier disruption: the role of cellular polyamines. BMC Microbiol. 2014, 14:19.
85. Olivares M., Castillejo G., Varea V., Sanz Y. Double-blind, randomised, placebo-controlled intervention trial to evaluate the effects of Bifidobacterium longum CECT 7347 in children with newly diagnosed coeliac disease. Br. J. Nutr. 2014, 112:30-40.
86. Smecuol E., Hwang H.J., Sugai E., Corso L., Chernavsky A.C., Bellavite F.P., et al. Exploratory, randomized, double-blind, placebo-controlled study on the effects of Bifidobacterium infantis natren life start strain super strain in active celiac disease. J. Clin. Gastroenterol. 2013, 47:139-147.
87. Goodrich J.K., Waters J.L., Poole A.C., Sutter J.L., Koren O., Blekhman R., et al. Human genetics shape the gut microbiome. Cell 2014, 159:789-799.
88. Frank D.N., Robertson C.E., Hamm C.M., Kpadeh Z., Zhang T., Chen H., et al. Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases. Inflamm. Bowel Dis. 2011, 17:179-184.
89. Rausch P., Rehman A., Kunzel S., Hasler R., Ott S.J., Schreiber S., et al. Colonic mucosa-associated microbiota is influenced by an interaction of Crohn disease and FUT2 (Secretor) genotype. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:19030-19035.
90. Olivares M., Neef A., Castillejo G., Palma G.D., Varea V., Capilla A., et al. The HLA-DQ2 genotype selects for early intestinal microbiota composition in infants at high risk of developing coeliac disease. Gut 2015, 64:406-417.
91. Kumar H., Lund R., Laiho A., Lundelin K., Ley R.E., Isolauri E., et al. Gut microbiota as an epigenetic regulator: pilot study based on whole-genome methylation analysis. mBio 2014, 5:e02113-e02114.
92. van de Wal Y., Kooy Y., van Veelen P., Pena S., Mearin L., Papadopoulos G., et al. Selective deamidation by tissue transglutaminase strongly enhances gliadin-specific T cell reactivity. J. Immunol. 1998, 161:1585-1588.
93. Johansen B.H., Vartdal F., Eriksen J.A., Thorsby E., Sollid L.M. Identification of a putative motif for binding of peptides to HLA-DQ2. Int. Immunol. 1996, 8:177-182.
94. Kim C.Y., Quarsten H., Bergseng E., Khosla C., Sollid L.M. Structural basis for HLA-DQ2-mediated presentation of gluten epitopes in celiac disease. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:4175-4179.
95. Lundin K.E., Scott H., Hansen T., Paulsen G., Halstensen T.S., Fausa O., et al. Gliadin-specific, HLA-DQ (alpha 1*0501,beta 1*0201) restricted T cells isolated from the small intestinal mucosa of celiac disease patients. J. Exp. Med. 1993, 178:187-196.
96. Molberg O., Kett K., Scott H., Thorsby E., Sollid L.M., Lundin K.E. Gliadin specific, HLA DQ2-restricted T cells are commonly found in small intestinal biopsies from coeliac disease patients, but not from controls. Scand. J. Immunol. 1997, 46:103-109.
97. Lundin K.E., Scott H., Fausa O., Thorsby E., Sollid L.M. T cells from the small intestinal mucosa of a DR4, DQ7/DR4, DQ8 celiac disease patient preferentially recognize gliadin when presented by DQ8. Hum. Immunol. 1994, 41:285-291.
98. Hausch F., Shan L., Santiago N.A., Gray G.M., Khosla C. Intestinal digestive resistance of immunodominant gliadin peptides. Am. J. Physiol. Gastrointest. Liver Physiol. 2002, 283:G996-g1003.
99. Qiao S.W., Bergseng E., Molberg O., Jung G., Fleckenstein B., Sollid L.M. Refining the rules of gliadin T cell epitope binding to the disease-associated DQ2 molecule in celiac disease: importance of proline spacing and glutamine deamidation. J. Immunol. 2005, 175:254-261.
100. Siegel M., Strnad P., Watts R.E., Choi K., Jabri B., Omary M.B., et al. Extracellular transglutaminase 2 is catalytically inactive, but is transiently activated upon tissue injury. PloS One 2008, 3:e1861.
101. Dieterich W., Ehnis T., Bauer M., Donner P., Volta U., Riecken E.O., et al. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat. Med. 1997, 3:797-801.
102. Vader W., Stepniak D., Kooy Y., Mearin L., Thompson A., van Rood J.J., et al. The HLA-DQ2 gene dose effect in celiac disease is directly related to the magnitude and breadth of gluten-specific T cell responses. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:12390-12395.
103. Bodd M., Kim C.Y., Lundin K.E., Sollid L.M. T-cell response to gluten in patients with HLA-DQ2.2 reveals requirement of peptide-MHC stability in celiac disease. Gastroenterology 2012, 142:552-561.
104. Fallang L.E., Bergseng E., Hotta K., Berg-Larsen A., Kim C.Y., Sollid L.M. Differences in the risk of celiac disease associated with HLA-DQ2.5 or HLA-DQ2.2 are related to sustained gluten antigen presentation. Nat. Immunol. 2009, 10:1096-1101.
105. Henderson K.N., Tye-Din J.A., Reid H.H., Chen Z., Borg N.A., Beissbarth T., et al. A structural and immunological basis for the role of human leukocyte antigen DQ8 in celiac disease. Immunity 2007, 27:23-34.
106. Bergseng E., Dorum S., Arntzen M.O., Nielsen M., Nygard S., Buus S., et al. Different binding motifs of the celiac disease-associated HLA molecules DQ2.5, DQ2.2, and DQ7.5 revealed by relative quantitative proteomics of endogenous peptide repertoires. Immunogenetics 2015, 67:73-84.
107. Diaz G., Amicosante M., Jaraquemada D., Butler R.H., Guillen M.V., Sanchez M., et al. Functional analysis of HLA-DP polymorphism: a crucial role for DPbeta residues 9, 11, 35, 55, 56, 69 and 84-87 in T cell allorecognition and peptide binding. Int. Immunol. 2003, 15:565-576.
108. Noble J.A., Valdes A.M., Thomson G., Erlich H.A. The HLA class II locus DPB1 can influence susceptibility to type 1 diabetes. Diabetes 2000, 49:121-125.
109. Yoshimura S., Isobe N., Yonekawa T., Matsushita T., Masaki K., Sato S., et al. Genetic and infectious profiles of Japanese multiple sclerosis patients. PloS One 2012, 7:e48592.
110. Fernando M.M., Freudenberg J., Lee A., Morris D.L., Boteva L., Rhodes B., et al. Transancestral mapping of the MHC region in systemic lupus erythematosus identifies new independent and interacting loci at MSH5, HLA-DPB1 and HLA-G. Ann. Rheumat. Dis. 2012, 71:777-784.
111. Lee N., Ishitani A., Geraghty D.E. HLA-F is a surface marker on activated lymphocytes. Eur. J. Immunol. 2010, 40:2308-2318.
112. Goodridge J.P., Lee N., Burian A., Pyo C.W., Tykodi S.S., Warren E.H., et al. HLA-F and MHC-I open conformers cooperate in a MHC-I antigen cross-presentation pathway. J. Immunol. 2013, 191:1567-1577.
113. Patsopoulos N.A., Barcellos L.F., Hintzen R.Q., Schaefer C., van Duijn C.M., Noble J.A., et al. Fine-mapping the genetic association of the major histocompatibility complex in multiple sclerosis: HLA and non-HLA effects. PLoS Genet. 2013, 9:e1003926.
114. Mikk M.L., Kiviniemi M., Laine A.P., Harkonen T., Veijola R., Simell O., et al. The HLA-B*39 allele increases type 1 diabetes risk conferred by HLA-DRB1*04:04-DQB1*03:02 and HLA-DRB1*08-DQB1*04 class II haplotypes. Hum. Immunol. 2014, 75:65-70.
115. Maccioni H.J., Quiroga R., Ferrari M.L. Cellular and molecular biology of glycosphingolipid glycosylation. J. Neurochem. 2011, 117:589-602.
116. Koning F. Pathophysiology of celiac disease. J. Pediatr. Gastroenterol. Nutr. 2014, 59(Suppl. 1):S1-S4.
117. Jabri B., Sollid L.M. Mechanisms of disease: immunopathogenesis of celiac disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 2006, 3:516-525.
118. Kaukinen K., Peraaho M., Collin P., Partanen J., Woolley N., Kaartinen T., et al. Small-bowel mucosal transglutaminase 2-specific IgA deposits in coeliac disease without villous atrophy: a prospective and randomized clinical study. Scand. J. Gastroenterol. 2005, 40:564-572.
119. Plaza-Izurieta L., Castellanos-Rubio A., Irastorza I., Fernandez-Jimenez N., Gutierrez G., Bilbao J.R. Revisiting genome wide association studies (GWAS) in coeliac disease: replication study in Spanish population and expression analysis of candidate genes. J. Med. Genet. 2011, 48:493-496.
120. Amundsen S.S., Viken M.K., Sollid L.M., Lie B.A. Coeliac disease-associated polymorphisms influence thymic gene expression. Genes Immun. 2014, 15:355-360.
121. Fernandez-Jimenez N., Castellanos-Rubio A., Plaza-Izurieta L., Irastorza I., Elcoroaristizabal X., Jauregi-Miguel A., et al. Coregulation and modulation of NFkappaB-related genes in celiac disease: uncovered aspects of gut mucosal inflammation. Hum. Mol. Genet. 2014, 23:1298-1310.
122. Green P.H., Cellier C. Celiac disease. N. Engl. J. Med. 2007, 357:1731-1743.
123. Mesin L., Sollid L.M., Di Niro R. The intestinal B-cell response in celiac disease. Front. Immunol. 2012, 3:313.
124. Matysiak-Budnik T., Moura I.C., Arcos-Fajardo M., Lebreton C., Menard S., Candalh C., et al. Secretory IgA mediates retrotranscytosis of intact gliadin peptides via the transferrin receptor in celiac disease. J. Exp. Med. 2008, 205:143-154.
125. Tortora R., Capone P., De Stefano G., Imperatore N., Gerbino N., Donetto S., et al. Metabolic syndrome in patients with coeliac disease on a gluten-free diet. Alimentary Pharmacol. Ther. 2015, 41:352-359.
126. Shepherd S.J., Gibson P.R. Nutritional inadequacies of the gluten-free diet in both recently-diagnosed and long-term patients with coeliac disease. J. Hum. Nutr. Dietetics Off. J. Br. Dietetic Assoc. 2013, 26:349-358.
127. Casellas F., Rodrigo L., Lucendo A.J., Fernandez-Banares F., Molina-Infante J., Vivas S., et al. Benefit on health-related quality of life of adherence to gluten-free diet in adult patients with celiac disease. Rev. Espanola Enfermedades Dig. Organo la Soc. Espanola Patol. Dig. 2015, 107:196-201.
128. Webb C., Myleus A., Norstrom F., Hammarroth S., Hogberg L., Lagerqvist C., et al. High adherence to a gluten-free diet in adolescents with screening-detected celiac disease. J. Pediatr. Gastroenterol. Nutr. 2015, 60:54-59.
129. Ellis H.J., Pollock E.L., Engel W., Fraser J.S., Rosen-Bronson S., Wieser H., et al. Investigation of the putative immunodominant T cell epitopes in coeliac disease. Gut 2003, 52:212-217.
130. Anderson R.P., van Heel D.A., Tye-Din J.A., Jewell D.P., Hill A.V. Antagonists and non-toxic variants of the dominant wheat gliadin T cell epitope in coeliac disease. Gut 2006, 55:485-491.
131. Xia J., Bergseng E., Fleckenstein B., Siegel M., Kim C.Y., Khosla C., et al. Cyclic and dimeric gluten peptide analogues inhibiting DQ2-mediated antigen presentation in celiac disease. Bioorg. Med. Chem. 2007, 15:6565-6573.
132. Siegel M., Xia J., Khosla C. Structure-based design of alpha-amido aldehyde containing gluten peptide analogues as modulators of HLA-DQ2 and transglutaminase 2. Bioorg. Med. Chem. 2007, 15:6253-6261.
133. Mitea C., Salentijn E.M., van Veelen P., Goryunova S.V., van der Meer I.M., van den Broeck H.C., et al. A universal approach to eliminate antigenic properties of alpha-gliadin peptides in celiac disease. PloS One 2010, 5:e15637.
134. Juse U., van de Wal Y., Koning F., Sollid L.M., Fleckenstein B. Design of new high-affinity peptide ligands for human leukocyte antigen-DQ2 using a positional scanning peptide library. Hum. Immunol. 2010, 71:475-481.
135. Kapoerchan V.V., Wiesner M., Hillaert U., Drijfhout J.W., Overhand M., Alard P., et al. Design, synthesis and evaluation of high-affinity binders for the celiac disease associated HLA-DQ2 molecule. Mol. Immunol. 2010, 47:1091-1097.
136. Offner H., Sinha S., Burrows G.G., Ferro A.J., Vandenbark A.A. RTL therapy for multiple sclerosis: a phase I clinical study. J. Neuroimmunol. 2011, 231:7-14.
137. Adamus G., Burrows G.G., Vandenbark A.A., Offner H. Treatment of autoimmune anterior uveitis with recombinant TCR ligands. Investigative Ophthalmol. Vis. Sci. 2006, 47:2555-2561.
138. Huan J., Kaler L.J., Mooney J.L., Subramanian S., Hopke C., Vandenbark A.A., et al. MHC class II derived recombinant T cell receptor ligands protect DBA/1LacJ mice from collagen-induced arthritis. J. Immunol. 2008, 180:1249-1257.
139. Huan J., Meza-Romero R., Mooney J.L., Vandenbark A.A., Offner H., Burrows G.G. Single-chain recombinant HLA-DQ2.5/peptide molecules block alpha2-gliadin-specific pathogenic CD4+ T-cell proliferation and attenuate production of inflammatory cytokines: a potential therapy for celiac disease. Mucosal Immunol. 2011, 4:112-120.
140. Zhernakova A., Withoff S., Wijmenga C. Clinical implications of shared genetics and pathogenesis in autoimmune diseases. Nat. Rev. Endocrinol. 2013, 9:646-659.
141. Pauley K.M., Cha S., Chan E.K. MicroRNA in autoimmunity and autoimmune diseases. J. Autoimmun. 2009, 32:189-194.
142. Esteller M. Non-coding RNAs in human disease. Nat. Rev. Genet. 2011, 12:861-874.
143. Zhou X., Jeker L.T., Fife B.T., Zhu S., Anderson M.S., McManus M.T., et al. Selective miRNA disruption in Treg cells leads to uncontrolled autoimmunity. J. Exp. Med. 2008, 205:1983-1991.
144. Yu D., Tan A.H., Hu X., Athanasopoulos V., Simpson N., Silva D.G., et al. Roquin represses autoimmunity by limiting inducible T-cell co-stimulator messenger RNA. Nature 2007, 450:299-303.
145. Liston A., Lu L.F., O'Carroll D., Tarakhovsky A., Rudensky A.Y. Dicer-dependent microRNA pathway safeguards regulatory T cell function. J. Exp. Med. 2008, 205:1993-2004.
146. Mardini H.E., Westgate P., Grigorian A.Y. Racial Differences in the prevalence of celiac disease in the US population: national health and nutrition examination survey (NHANES) 2009-2012. Dig. Dis. Sci. 2015, 60:1738-1742.
147. Remes-Troche J.M., Nunez-Alvares C., Uscanga-Dominguez L.F. Celiac disease in Mexican population: an update. Am. J. Gastroenterol. 2013, 108:283-284.
148. Galvan J.A., Lemos G., Fernandez de Cossio M.E., Ruenes C., Martinez Y., Tejeda Y., et al. Silent celiac disease in a cohort of healthy adults. Autoimmunity 2009, 42:705-708.
149. Pratesi R., Gandolfi L., Garcia S.G., Modelli I.C., Lopes de Almeida P., Bocca A.L., et al. Prevalence of coeliac disease: unexplained age-related variation in the same population. Scand. J. Gastroenterol. 2003, 38:747-750.
150. Alencar M.L., Ortiz-Agostinho C.L., Nishitokukado L., Damiao A.O., Abrantes-Lemos C.P., Leite A.Z., et al. Prevalence of celiac disease among blood donors in Sao Paulo: the most populated city in Brazil. Clinics (Sao Paulo, Brazil) 2012, 67:1013-1018.
151. Gomez J.C., Selvaggio G.S., Viola M., Pizarro B., la Motta G., de Barrio S., et al. Prevalence of celiac disease in Argentina: screening of an adult population in the La Plata area. Am. J. Gastroenterol. 2001, 96:2700-2704.
152. Mora M., Litwin N., Toca Mdel C., Azcona M.I., Solis Neffa R., Battiston F., et al. Prevalence of celiac disease: multicentric trial among pediatric population from five urban districts in Argentina. Arch. Argent. Pediatr. 2012, 110:490-496.
153. Catassi C., Ratsch I.M., Gandolfi L., Pratesi R., Fabiani E., El Asmar R., et al. Why is coeliac disease endemic in the people of the Sahara?. Lancet 1999, 354:647-648.
154. Cataldo F., Lio D., Simpore J., Musumeci S. Consumption of wheat foodstuffs not a risk for celiac disease occurrence in burkina faso. J. Pediatr. Gastroenterol. Nutr. 2002, 35:233-234.
155. Hariz M.B., Laadhar L., Kallel-Sellami M., Siala N., Bouraoui S., Bouziri S., et al. Celiac disease in Tunisian children: a second screening study using a "new generation" rapid test. Immunol. Investig. 2013, 42:356-368.
156. Alarida K., Harown J., Ahmaida A., Marinelli L., Venturini C., Kodermaz G., et al. Coeliac disease in Libyan children: a screening study based on the rapid determination of anti-transglutaminase antibodies. Dig. Liver Dis. Off. J. Italian Soc. Gastroenterol. Italian Assoc. Study Liver 2011, 43:688-691.
157. Abu-Zekry M., Kryszak D., Diab M., Catassi C., Fasano A. Prevalence of celiac disease in Egyptian children disputes the east-west agriculture-dependent spread of the disease. J. Pediatr. Gastroenterol. Nutr. 2008, 47:136-140.
158. Antunes H., Abreu I., Nogueiras A., Sa C., Goncalves C., Cleto P., et al. First determination of the prevalence of celiac disease in a Portuguese population. Acta Medica Port. 2006, 19:115-120.
159. Marine M., Farre C., Alsina M., Vilar P., Cortijo M., Salas A., et al. The prevalence of coeliac disease is significantly higher in children compared with adults. Alimentary Pharmacol. Ther. 2011, 33:477-486.
160. Johnston S.D., Watson R.G., McMillan S.A., Sloan J., Love A.H. Prevalence of coeliac disease in Northern Ireland. Lancet 1997, 350:1370.
161. West J., Fleming K.M., Tata L.J., Card T.R., Crooks C.J. Incidence and prevalence of celiac disease and dermatitis herpetiformis in the UK over two decades: population-based study. Am. J. Gastroenterol. 2014, 109:757-768.
162. Rostami K., Mulder C.J., Werre J.M., van Beukelen F.R., Kerchhaert J., Crusius J.B., et al. High prevalence of celiac disease in apparently healthy blood donors suggests a high prevalence of undiagnosed celiac disease in the Dutch population. Scand. J. Gastroenterol. 1999, 34:276-279.
163. Csizmadia C.G., Mearin M.L., von Blomberg B.M., Brand R., Verloove-Vanhorick S.P. An iceberg of childhood coeliac disease in the Netherlands. Lancet 1999, 353:813-814.
164. Kratzer W., Kibele M., Akinli A., Porzner M., Boehm B.O., Koenig W., et al. Prevalence of celiac disease in Germany: a prospective follow-up study. World J. Gastroenterol. WJG 2013, 19:2612-2620.
165. Nenna R., Tiberti C., Petrarca L., Lucantoni F., Mennini M., Luparia R.P., et al. The celiac iceberg: characterization of the disease in primary schoolchildren. J. Pediatr. Gastroenterol. Nutr. 2013, 56:416-421.
166. Maki M., Mustalahti K., Kokkonen J., Kulmala P., Haapalahti M., Karttunen T., et al. Prevalence of celiac disease among children in Finland. N. Engl. J. Med. 2003, 348:2517-2524.
167. Stordal K., Bakken I.J., Suren P., Stene L.C. Epidemiology of coeliac disease and comorbidity in Norwegian children. J. Pediatr. Gastroenterol. Nutr. 2013, 57:467-471.
168. Ress K., Harro M., Maaroos H.I., Harro J., Uibo R., Uibo O. High prevalence of coeliac disease: need for increasing awareness among physicians. Dig. Liver Dis. Off. J. Italian Soc. Gastroenterol. Italian Assoc. Study Liver 2007, 39:136-139.
169. Leja M., Shums Z., Nikitina-Zake L., Gavars M., Kikuste I., Milo J., et al. Prevalence estimation of celiac disease in the general adult population of Latvia using serology and HLA genotyping. United Eur. Gastroenterol. J. 2015, 3:190-199.
170. Horwitz A., Skaaby T., Karhus L.L., Schwarz P., Jorgensen T., Rumessen J.J., et al. Screening for celiac disease in Danish adults. Scand. J. Gastroenterol. 2015, 50:824-831.
171. Karagiozoglou-Lampoudi T., Zellos A., Vlahavas G., Kafritsa Y., Roma E., Papadopoulou A., et al. Screening for coeliac disease in preschool Greek children: the feasibility study of a community-based project. Acta Paediatr. 2013, 102:749-754.
172. Sardy M., Kornsee Z., Kelemen D., Papp S., Medvecz M., Karpati S. Celiac disease screening among healthy blood donors in Hungary. Z. Fur Gastroenterol. 2013, 51:1235-1239.
173. Nusier M.K., Brodtkorb H.K., Rein S.E., Odeh A., Radaideh A.M., Klungland H. Serological screening for celiac disease in schoolchildren in Jordan. Is height and weight affected when seropositive?. Italian J. Pediatr. 2010, 36:16.
174. Shamir R., Lerner A., Shinar E., Lahat N., Sobel E., Bar-or R., et al. The use of a single serological marker underestimates the prevalence of celiac disease in Israel: a study of blood donors. Am. J. Gastroenterol. 2002, 97:2589-2594.
175. Aljebreen A.M., Almadi M.A., Alhammad A., Al Faleh F.Z. Seroprevalence of celiac disease among healthy adolescents in Saudi Arabia. World J. Gastroenterol. WJG 2013, 19:2374-2378.
176. Abu-Zeid Y.A., Jasem W.S., Lebwohl B., Green P.H., ElGhazali G. Seroprevalence of celiac disease among United Arab Emirates healthy adult nationals: a gender disparity. World J. Gastroenterol. WJG 2014, 20:15830-15836.
177. Dalgic B., Sari S., Basturk B., Ensari A., Egritas O., Bukulmez A., et al. Prevalence of celiac disease in healthy Turkish school children. Am. J. Gastroenterol. 2011, 106:1512-1517.
178. Farahmand F., Mir-Nasseri M.M., Shahraki T., Yourdkhani F., Ghotb S., Modaresi V., et al. Prevalence of occult celiac disease in healthy Iranian school age children. Arch. Iran. Med. 2012, 15:342-345.
179. Dehghani S.M., Haghighat M., Mobayen A., Rezaianzadeh A., Geramizadeh B. Prevalence of celiac disease in healthy Iranian school children. Ann. Saudi Med. 2013, 33:159-161.
180. Kondrashova A., Mustalahti K., Kaukinen K., Viskari H., Volodicheva V., Haapala A.M., et al. Lower economic status and inferior hygienic environment may protect against celiac disease. Ann. Med. 2008, 40:223-231.
181. Bhattacharya M., Dubey A.P., Mathur N.B. Prevalence of celiac disease in north Indian children. Indian Pediatr. 2009, 46:415-417.
182. Kochhar R., Sachdev S., Kochhar R., Aggarwal A., Sharma V., Prasad K.K., et al. Prevalence of coeliac disease in healthy blood donors: a study from north India. Dig. Liver Dis. Off. J. Italian Soc. Gastroenterol. Italian Assoc. Study Liver 2012, 44:530-532.
183. Yap T.W., Chan W.K., Leow A.H., Azmi A.N., Loke M.F., Vadivelu J., et al. Prevalence of serum celiac antibodies in a multiracial Asian population-a first study in the young Asian adult population of Malaysia. PloS One 2015, 10:e0121908.
184. Cook H.B., Burt M.J., Collett J.A., Whitehead M.R., Frampton C.M., Chapman B.A. Adult coeliac disease: prevalence and clinical significance. J. Gastroenterol. Hepatol. 2000, 15:1032-1036.
185. Hovell C.J., Collett J.A., Vautier G., Cheng A.J., Sutanto E., Mallon D.F., et al. High prevalence of coeliac disease in a population-based study from Western Australia: a case for screening?. Med. J. Aust. 2001, 175:247-250.